GWS
VRTX icon

Glassman Wealth Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Glassman Wealth Services’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-349
Closed -$142K – 1780
2023
Q4 		$142K Buy
349
+4
+1% +$1.48K 0.02% 244
2023
Q3 		$120K Buy
345
+2
+0.6% +$699 0.02% 246
2023
Q2 		$121K Buy
343
+1
+0.3% +$337 0.02% 242
2023
Q1 		$108K Buy
342
+34
+11% +$10.2K 0.02% 254
2022
Q4 		$88.9K Buy
308
+11
+4% +$3.35K 0.02% 289
2022
Q3 		$86K Buy
297
+17
+6% +$4.89K 0.02% 270
2022
Q2 		$79K Buy
280
+47
+20% +$12.6K 0.02% 300
2022
Q1 		$61K Sell
233
-95
-29% -$22.5K 0.01% 360
2021
Q4 		$72K Buy
328
+218
+198% +$42.4K 0.01% 303
2021
Q3 		$20K Buy
110
+10
+10% +$1.95K ﹤0.01% 584
2021
Q2 		$20K Sell
100
-8
-7% -$1.67K ﹤0.01% 579
2021
Q1 		$23K Buy
108
+18
+20% +$3.95K ﹤0.01% 495
2020
Q4 		$21K Sell
90
-82
-48% -$18.8K ﹤0.01% 513
2020
Q3 		$47K Buy
172
+48
+39% +$13.2K 0.01% 305
2020
Q2 		$36K Buy
124
+33
+36% +$8.95K 0.01% 300
2020
Q1 		$22K Sell
91
-17
-16% -$3.9K 0.01% 330
2019
Q4 		$24K Buy
108
+3
+3% +$607 0.01% 355
2019
Q3 		$18K Buy
105
+18
+21% +$3.18K 0.01% 374
2019
Q2 		$16K Sell
87
-9
-9% -$1.57K 0.01% 394
2019
Q1 		$18K Buy
96
+66
+220% +$12.2K 0.01% 370
2018
Q4 		$5K Hold
30
– – ﹤0.01% 437
2018
Q3 		$6K Sell
30
-3
-9% -$534 ﹤0.01% 463
2018
Q2 		$6K Buy
33
+5
+18% +$775 ﹤0.01% 427
2018
Q1 		$5K Hold
28
– – ﹤0.01% 434
2017
Q4 		$4K Buy
28
+3
+12% +$444 ﹤0.01% 441
2017
Q3 		$4K Hold
25
– – ﹤0.01% 378
2017
Q2 		$3K Hold
25
– – ﹤0.01% 404
2017
Q1 		$3K Sell
25
-68
-73% -$5.99K ﹤0.01% 432
2016
Q4 		$7K Buy
93
+89
+2,225% +$7.24K 0.01% 409
2016
Q3 		$0 Buy
+4
New +$378 ﹤0.01% 590

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Glassman Wealth Services's VRTX Position: Q1 2024 in Review

Glassman Wealth Services sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 349 shares — an estimated $142K sold.

Glassman Wealth Services first reported a position in VRTX in Q3 2016 and held it in 30 quarters. The position peaked at $142K in Q4 2023. 1,496 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Glassman Wealth Services reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Glassman Wealth Services sold 349 Vertex Pharmaceuticals shares in Q1 2024, an estimated $142K.
  • Glassman Wealth Services first reported a position in Vertex Pharmaceuticals in Q3 2016 and held it in 30 quarters.
  • Glassman Wealth Services's Vertex Pharmaceuticals position peaked at $142K in Q4 2023.
  • 1,496 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Glassman Wealth Services's 13F filing for Q1 2024, filed 3 May 2024.